|

Home / Research / Publications / Clinical Impact of Matched Plasma & WBC DNA Sequencing for Variant-origin Classification of PARP Inhibitor-associated Alterations in Prostate Cancer

Innovation

Publications

Clinical Impact of Matched Plasma & WBC DNA Sequencing for Variant-origin Classification of PARP Inhibitor-associated Alterations in Prostate Cancer

 Conclusions 

  • A significant proportion of prostate cancer patients undergoing liquid profiling have PARPi-associated HRR variants detected only as CH, especially in ATM and CHEK2. 
  • These findings identify a clinically meaningful risk of variant misclassification of HRR variants in prostate cancer with plasma-only testing. 
  • Simultaneous sequencing of matched WBC DNA distinguishes CH-derived HRR variants from actionable HRR variants, informing appropriate patient selection for PARPi therapy. 

Download Publication
Learn More